Drug conjugate comprising an erythropoietin receptor ligand and an anticancer agent
US7344699B2 · kind B2 · utility
21Cited by
1References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 21, 2003 |
| Grant date | Mar 18, 2008 |
| Priority date | — |
| Expiry date | May 21, 2023 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/64
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A drug conjugate comprising a targeting agent and an anti-cancer agent, wherein said targeting agent comprises an erythropoietin receptor ligand, is described. The drug conjugate can be used in methods of treating cancer. Also described are methods of treating cancer using the conjugate, methods of diagnosis, methods of imaging and pharmaceutical compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.